Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site. # Sonic Incytes the creators of Velacur ## Sitemaps - [XML Sitemap](https://www.sonicincytes.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases](https://www.sonicincytes.com/fda-grants-510k-clearance-to-sonic-incytes-velacur-one/) - VANCOUVER, British Columbia–(BUSINESS WIRE)–Sonic Incytes Medical Corp, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE™, its point-of-care ultrasound elastography device. Building on the success of its original model, Velacur™, Velacur ONE™ introduces an enhanced interface and features for improved portability and user experience. These improvements enable - [Liver Elastography: CPT Codes, Common Mistakes & Best Practices for Billing](https://www.sonicincytes.com/liver-elastography-76981-cpt-code-description/) - Ensuring proper use of CPT codes for liver elastography not only facilitates smooth reimbursements but also helps avoid unnecessary claim denials. At Sonic Incytes, we are committed to providing healthcare providers with the knowledge they need to bill correctly and maximize reimbursement. This article outlines: CPT codes for liver elastography, including a description of CPT - [Capital Digestive Care increases liver elastography volume by 171% with Velacur](https://www.sonicincytes.com/capital-digestive-care-increases-liver-elastography-volume/) - FATTY LIVER DISEASE Fatty liver disease is the fastest-growing segment of chronic liver disease, with an estimated one in three adults suffering from Metabolic Dysfunction-Associated Steatotic Liver Disease aka. MASLD (previously NAFLD) . In parallel, NALFD related mortality has been steadily increasing since the early 90s. CAPITAL DIGESTIVE CARE Case study site: Norfolk, VA - [FDA Grants 510(k) Clearance to Sonic Incytes' Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH](https://www.sonicincytes.com/fda-grants-510k-clearance-velacur-determined-fat-fraction/) - VANCOUVER, British Columbia — (BUSINESS WIRE) — Sonic Incytes Medical Corp, a leader in point-of-care ultrasound, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Velacur® Determined Fat Fraction (VDFF). This innovative measurement tool is integrated into the Velacur® device software, combining quantitative measures of ultrasound attenuation and - [Sonic Incytes Recognized at 2023 LSBC Awards Gala](https://www.sonicincytes.com/sonic-incytes-recognized-at-2023-lsbc-awards-gala/) - Sonic Incytes was recognized as a "Company to Watch" at the 25th Annual LSBC Awards Gala, presented by Farris. This recognition underscores Sonic Incytes' commitment to healthcare innovation and its groundbreaking product, Velacur, which is contributing to the fight against the global epidemic of non-alcoholic fatty liver disease—a condition that impacts nearly 30% of the - [Sonic Incytes to Present Data at EASL International Liver Congress™️ 2023](https://www.sonicincytes.com/sonic-incytes-to-present-data-at-easl-international-liver-congress-2023/) - Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification We are excited to announce that clinical data from Sonic Incytes’ multi-center study will be presented at the prestigious European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 in Vienna, Austria. The poster presentation highlights the comparison between point-of-care liver quantification tools, - [Sonic Incytes Receives FDA 510(k) Clearance of AI Powered Features for Velacur™️ Liver Ultrasound](https://www.sonicincytes.com/sonic-incytes-receives-fda-510k-clearance-of-ai-powered-features-for-velacur️-liver-ultrasound/) - Sonic Incytes is pleased to announce they have received Food and Drug Administration (FDA) clearance for new Organ Guide and Wave Quality Detector features for Velacur™️, the Company’s liver diagnostic tool. These new artificial intelligence and machine learning (AI-ML)-based tools will improve the accuracy and performance of the device and enable less experienced medical personnel - [Sonic Incytes Announces New Non-Dilutive Funding to Enhance Company's Velacur™️ Medical Device](https://www.sonicincytes.com/sonic-incytes-announces-new-non-dilutive-funding/) - Sonic Incytes Medical Corp. is pleased to announce its project was selected for investment by the inaugural INOVAIT Focus Fund. INOVAIT is a pan-Canadian network funded by the Government of Canada that invests strategically in projects at the intersection of advanced imaging, minimally-invasive therapies, and artificial intelligence (AI). Through this three-year, non-repayable investment, the Company - [Sonic Incytes Announces Clinical Trial Data Comparing Velacur™️ and FibroScan®](https://www.sonicincytes.com/sonic-incytes-announces-clinical-trial-data-comparing-velacur-and-fibroscan/) - Sonic Incytes Medical Corp. is pleased to announce clinical data from a prospective multi-center study comparing the effectiveness of Velacur™️ and FibroScan® in measuring liver fibrosis and fat in patients with suspected NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). The results confirmed earlier findings that Velacur can effectively differentiate between various stages of - [Sonic Incytes Announces Velacur™️ use in Madrigal Pharmaceuticals’ Open-Label Extension Clinical Trial](https://www.sonicincytes.com/sonic-incytes-announces-velacur-use-in-madrigal-pharmaceuticals-trial/) - Sonic Incytes Medical Corp. is pleased to announce the inclusion of Velacur™️ — the first handheld 3D liver health assessment tool—in a subset of Madrigal Pharmaceutical’s MAESTRO NAFLD-1 Phase 3 Open Label Extension study of resmetirom (MGL-3196-18). As part of this Madrigal study, a subset of patients will undergo VelacurTM imaging at baseline (Day 1), Week - [Sonic Incytes Receives Award at 2022 Digestive Disease Week Conference](https://www.sonicincytes.com/sonic-incytes-receives-award-at-2022-digestive-disease-week-conference/) - The poster entitled “Accuracy of Velacur™️ AI Powered Liver Guide in Identification of Liver” presented at the Digestive Disease Week (DDW) Conference in San Diego, California received a Poster of Distinction Award. The poster reported on results from a multi-center study carried out to assess the performance of a new AI powered liver guide being - [Metabolic Syndrome: Myths, Assessment Tools, Novel Treatments and More](https://www.sonicincytes.com/metabolic-syndrome-myths-assessment-tools-novel-treatments/) - Metabolic syndrome is a cluster of conditions that increase the risk of many chronic illnesses such as heart disease, stroke, diabetes and liver disease. One-third of US adults have metabolic syndrome, including 80 per cent of those who are obese. This disease is a chronic inflammatory condition and it’s treatable. According to renowned bariatric surgeon - [Register for Novel Tools for Managing Metabolic Syndrome](https://www.sonicincytes.com/register-for-novel-tools-for-managing-metabolic-syndrome/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Novel Tools for Managing Metabolic Syndrome. Metabolic syndrome is a growing public health issue affecting 1 in 3 Americans. Left untreated, it greatly increases the risk of many chronic illnesses including diabetes, heart disease, and liver disease. Join renowned bariatric surgeon and - [Sonic Incytes Appoints New CEO and Chair to Accelerate Growth](https://www.sonicincytes.com/sonic-incytes-appoints-new-ceo-and-chair-to-accelerate-growth/) - Following the closing of its US$7.3M Series A raise in December 2021, the Sonic Incytes Medical Corp. Board of Directors is pleased to announce the appointment of Barry Allen as the new CEO and Natalie Dakers as the new Board Chair to lead the company through its next stage of growth. “Our focus is on - [Register for Owning NAFLD Via Reimbursement Optimization](https://www.sonicincytes.com/register-for-owning-nafld-via-reimbursement-optimization/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Owning NAFLD Via Reimbursement Optimization. Join former payer Dr. Gary Owens and revenue cycle management expert Satish Malnaik to discover how providers and payers can work together to address the emerging fatty liver disease epidemic, resulting in better patient outcomes with improved - [Sonic Incytes Selected to Pitch at Innovative HealthTech Competition](https://www.sonicincytes.com/sonic-incytes-selected-to-pitch-at-innovative-healthtech-competition/) - Sonic Incytes Medical Corp. has been selected as one of three finalists at the ADA’s 2021 Silicon Valley Leaders Forum HealthTech Showcase, taking place November 19, 2021 in San Mateo, California. Sponsored by Wilson Sonsini, this year’s event will focus on how health technology equity is enabling care for people living with vulnerable conditions. During - [Learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials](https://www.sonicincytes.com/learn-about-the-power-of-3d-liver-ultrasound-for-nash-clinical-trials/) - Join us virtually on December 1 at 10AMPT/12PM CT/1PM ET at the 5th Annual NASH Summit 2021 to learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials, featuring Dr. Stephen Harrison, Medical Director, Pinnacle Clinical Research & President, Summit Clinical Research; and George Aliphtiras, CEO, Sonic Incytes Medical Corp. Key takeaways include: - [Sonic Incytes Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization](https://www.sonicincytes.com/sonic-incytes-successfully-completes-series-a-raise-of-us7-3m-to-accelerate-velacurtm-commercialization/) - Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors. - [Sonic Incytes Showcases VelacurTM at ACG 2021](https://www.sonicincytes.com/sonic-incytes-showcases-velacur-at-acg-2021/) - In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of Gastroenterology (ACG) Annual Scientific Meeting, Oct 22-27. - [VelacurTM Data Presented at 2021 AASLD The Liver Meeting](https://www.sonicincytes.com/velacur-data-presented-at-aasld-2021/) - Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health assessment solution – will be presented during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, hosted virtually November 12-15, 2021. - [A Master Builder of HealthTech that Matters](https://www.sonicincytes.com/a-master-builder-of-healthtech-that-matters/) - There is a certain thrill when you find parts and use them to build something new. For Sonic Incytes’ Lead Hardware Engineer Mohammad Honarvar, the whole is truly greater than the sum of its parts. Growing up, Mohammad spent much of his time in his dad’s machine shop, watching him fix everything. It wasn’t long - [Join Sonic Incytes at ACG 2021](https://www.sonicincytes.com/join-sonic-incytes-at-acg-2021/) - You’re invited! Join Sonic Incytes at ACG 2021. VelacurTM, the first handheld 3D liver health assessment solution, is coming to ACG 2021. If you care for patients with chronic liver disease or are interested in building your practice, we invite you to connect with us at the ACG 2021 Annual Scientific Meeting in Las Vegas. - [Discover VelacurTM at the Annual National Liver Conference](https://www.sonicincytes.com/discover-velacurtm-at-the-annual-national-liver-conference/) - If you practice in the field of liver disease, visit our booth at the 16th Annual National Liver Conference to learn more about VelacurTM, the first handheld 3D liver health assessment solution. Hosted October 1, 2021, this conference is intended for physicians and other health care professionals engaged in the care of patients with liver - [Discover How You Can Grow Your Practice with VelacurTM at TSGE 2021](https://www.sonicincytes.com/discover-how-you-can-grow-your-practice-with-velacurtm-at-tsge-2021/) - VelacurTM, the first handheld 3D liver health assessment solution, is coming to the 2021 Annual TSGE Conference, September 24 to 26! If you care for patients with chronic liver disease (including fatty liver disease) or are interested in building your practice, visit our booth for a live VelacurTM demo and to connect with our team. - [Visit VelacurTM at 2021 Annual GHAPP Conference](https://www.sonicincytes.com/visit-velacurtm-at-2021-annual-ghapp-conference/) - If you specialize in the management of patients with chronic liver disease, visit our booth at the 2021 Annual GHAPP Conference to learn more about VelacurTM, the first handheld 3D liver health assessment solution. Hosted September 9-11, the GHAPP Conference is the only conference specifically designed by and for advanced practice providers (APPs) to review - [Register for An Optimal Model of Care for NASH Webinar](https://www.sonicincytes.com/register-for-an-optimal-model-of-care-for-nash-webinar/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on The Multidisciplinary Approach: An Optimal Model of Care for NASH. Endocrinologist Dr. Kenneth Cusi and hepatologist Dr. Mazen Noureddin join forces to shine a light on the emerging fatty liver disease epidemic, and what it will take to overcome this health burden. - [On a Quest to Improve Quality of Life](https://www.sonicincytes.com/on-a-quest-to-improve-quality-of-life/) - As a young child, Julio Lobo loved solving problems. Fast forward to today, he’s been instrumental in helping build VelacurTM, a diagnostic solution for one of the world’s biggest problems: fatty liver disease. Affecting 1 in 4 people around the world, fatty liver disease is the fastest growing and largest segment of chronic liver disease, - [Visit VelacurTM at Advancing GI Patient Care 2021](https://www.sonicincytes.com/visit-velacurtm-at-advancing-gi-patient-care-2021/) - On July 24, find out how you can improve patient care for those with chronic liver disease at Advancing GI Patient Care 2021, an educational conference hosted by GI Alliance. Visit our in-person booth for live demos of VelacurTM, the first handheld 3D liver health assessment solution. Advancing GI Patient Care 2021 will deliver focused, - [Sonic Incytes to Present at the Venture Summit Virtual Connect](https://www.sonicincytes.com/sonic-incytes-to-present-at-the-venture-summit-virtual-connect/) - Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to present its innovative technology at the upcoming Venture Summit Virtual Connect conference, hosted by youngStartup Ventures from July 6-8, 2021. Sonic Incytes is among the top innovators from the technology, cleantech, life sciences, healthcare and fintech sectors chosen to present to an exclusive - [Our Lead Clinical Engineer Leads the Way](https://www.sonicincytes.com/our-lead-clinical-engineer-leads-the-way/) - While STEM runs in her blood, building things that have an impact and help people are true to her heart. Meet Caitlin Schneider: Sonic Incytes’ Lead Clinical Engineer, who helped build Velacur, the first handheld 3D liver health assessment solution, in the lab with leading experts in medical ultrasound imaging Dr. Tim Salcudean and Dr. - [Register for The Future of GI Webinar](https://www.sonicincytes.com/register-for-the-future-of-gi-webinar/) - Sonic Incytes is pleased to host the live educational webinar, Scope Forward: The Future of GI is Now in Your Hands. Join entrepreneur and healthcare futurist Praveen Suthrum and gastroenterologist Dr. Bradley Sklar to discover insights and practical advice for the industry to thrive, not just survive in the coming decade. Key points to be - [Sonic Incytes Selected for MedTech Innovator Asia Pacific Accelerator](https://www.sonicincytes.com/sonic-incytes-selected-for-medtech-innovator-asia-pacific-accelerator/) - MedTech Innovator, the largest accelerator of medical device companies in the world, in partnership with Asia Pacific Medical Technology Association, announced on June 21 that Sonic Incytes Medical Corp. has been selected to participate in the organization’s Asia Pacific Accelerator program. Every year, MedTech Innovator selects the best and brightest medtech start-ups that are seeking - [Are Your Patients at Risk? Fatty Liver Disease is a Silent, Deadly Epidemic](https://www.sonicincytes.com/are-your-patients-at-risk-fatty-liver-disease-is-a-silent-deadly-epidemic/) - If there ever was a more urgent time to talk to your patients about fatty liver disease that time is now. While the headlines have been screaming about COVID-19, there is another epidemic that has been concealed in silence. That is, an epidemic of fatty liver disease. Approximately 1 in 4 persons worldwide has fatty - [Are You at Risk? Fatty Liver Disease is a Silent, Deadly Epidemic](https://www.sonicincytes.com/are-you-at-risk-fatty-liver-disease-is-a-silent-deadly-epidemic/) - If there ever was a more urgent time to talk about fatty liver disease that time is now. While the headlines have been screaming about COVID-19, there is another epidemic that has been concealed in silence. That is, an epidemic of fatty liver disease. Approximately 1 in 4 persons worldwide has fatty liver disease, the - [Sonic Incytes Selected for RESI Innovator's Pitch Challenge](https://www.sonicincytes.com/sonic-incytes-selected-for-resi-innovators-pitch-challenge/) - Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to participate in the Innovator’s Pitch Challenge at the upcoming Redefining Early Stage Investments (RESI) conference, held digitally June 8-10, 2021. The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel - [Live Webinar: Advances in NASH Drugs & The Role of NITs](https://www.sonicincytes.com/live-webinar-advances-in-nash-drugs-the-role-of-nits/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Advances in NASH Drugs & The Role of NITs. Join presenter Dr. Stephen Harrison, a Key Opinion Leader in NASH, to learn about the exciting progress of NASH drugs and non-invasive tests in addressing this emerging health crisis. Key points to be - [Genome BC Invests $1M in Breakthrough Solution for Detecting Chronic Liver Disease, Closing Off Sonic Incytes’ $3.5M Financing Round](https://www.sonicincytes.com/genome-bc-invests-1m-in-breakthrough-solution-for-detecting-chronic-liver-disease-closing-off-sonic-incytes-3-5m-financing-round/) - Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals. - [Sonic Incytes Announces FDA Clearance and US Launch of VelacurTM to Help Manage Emerging Health Crisis](https://www.sonicincytes.com/sonic-incytes-announces-fda-clearance-and-us-launch-of-velacurtm-to-help-manage-emerging-health-crisis/) - Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to Magnetic Resonance Imaging (MRI). - [Sonic Incytes Selected as an Alternate in 2021 SXSW Pitch](https://www.sonicincytes.com/sonic-incytes-selected-as-an-alternate-in-2021-sxsw-pitch/) - Sonic Incytes Medical Corp., the developers of the first handheld 3D liver health assessment solution, was selected as an alternate in the Health, Wearables & Wellbeing category for the 13th annual SXSW Pitch, March 17-18, 2021. SXSW Pitch is a marquee event where leading start-ups from around the world showcase some of the most innovative - [Our Co-Founders’ Story: Paving the Way for a New Standard of Care in Assessing Liver Health](https://www.sonicincytes.com/our-co-founders-story-paving-the-way-for-a-new-standard-of-care-in-assessing-liver-health/) - It takes a certain type of person to be painstakingly driven to seek novel ways of making the impossible possible. Someone who is constantly curious, has grit, and loves to solve problems. Drs. Tim Salcudean and Robert Rohling, co-founders of Sonic Incytes Medical Corp., have these characteristics in spades. Salcudean and Rohling are leading experts - [Sonic Incytes Selected for MedTech Innovator Asia Pacific 2021 Road Tour](https://www.sonicincytes.com/sonic-incytes-selected-for-medtech-innovator-asia-pacific-2021-road-tour/) - Acknowledged for our mission to improve patient lives, Sonic Incytes Medical Corp. has been selected to pitch in the virtual MedTech Innovator Asia Pacific 2021 Road Tour on March 23, 2021 (PT). MedTech Innovator Asia Pacific is the premier competition for emerging medtech companies in the Asia Pacific region. Every year, MedTech Innovator selects the - [Live Webinar: Redefining the Standard of Care for Assessing Liver Health](https://www.sonicincytes.com/live-webinar-redefining-the-standard-of-care-for-assessing-liver-health/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Redefining the Standard of Care for Assessing Liver Health. Join presenters Dr. Tim Salcudean and Dr. Robert Rohling, leading experts and inventors in medical ultrasound imaging, to learn about: The Power of 3D Elastography in Measuring Liver Fibrosis How and Why Ultrasound - [Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row](https://www.sonicincytes.com/sonic-incytes-recognized-as-a-ready-to-rocket-company-for-second-year-in-a-row/) - Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket - [Sonic Incytes Selected for MedTech Innovator US 2021 Road Tour](https://www.sonicincytes.com/sonic-incytes-selected-for-medtech-innovator-us-2021-road-tour/) - Identified as best-in-class, Sonic Incytes Medical Corp. has been selected to pitch in the virtual MedTech Innovator US 2021 Road Tour on April 14, 2021. Every year, MedTech Innovator selects the best and brightest medtech start-ups that are seeking to improve patient lives through innovation. Sonic Incytes was selected to pitch among the more than 1000 - [Watch VelacurTM in Action at Liver Connect 2021](https://www.sonicincytes.com/watch-velacurtm-in-action-at-liver-connect-2021/) - If you’re ready to transform your liver practice, we’re ready to show you how. Discover how fast, accurate and easy VelacurTM is to assess liver health at the inaugural Liver Connect conference, April 16-17, 2021, hosted by the Chronic Liver Disease Foundation. Visit our in-person booth for live demos of Velacur, the first handheld 3D - [The Pandemic Diet: How COVID-19 Is Accelerating the Risk of Fatty Liver Disease](https://www.sonicincytes.com/the-pandemic-diet-how-covid-19-is-accelerating-the-risk-of-fatty-liver-disease/) - Did you turn to comfort food and cocktails during the pandemic? Well, you are not alone. According to the American Psychological Association’s survey of US adults in February 2021, the majority of adults (61 per cent) experienced undesired weight changes – weight gain or loss – since the pandemic started, with 42 per cent reporting they - [Sonic Incytes Takes the Stage at LSI Emerging Medtech Summit](https://www.sonicincytes.com/sonic-incytes-takes-the-stage-at-lsi-emerging-medtech-summit/) - Sonic Incytes Medical Corp., the developers of VelacurTM, will take the stage at the LSI 2021 Emerging Medtech Summit to present its breakthrough solution for addressing fatty liver disease, an urgent, global health crisis exacerbated by the COVID-19 pandemic. Held May 11-13 in California, this premier event connects start-ups that have developed the most innovative - [Visit VelacurTM at NASH-TAG 2021](https://www.sonicincytes.com/visit-velacurtm-at-nash-tag-2021/) - Discover how fast, accurate and easy VelacurTM is to assess liver health at the NASH-TAG Conference, March 11-13, 2021. Read our poster and visit our in-person booth for live demos of Velacur, the first handheld 3D liver health assessment solution. Developed by Sonic Incytes Medical Corp., VelacurTM is a breakthrough, point of care ultrasound solution that - [Sonic Incytes Introduces VelacurTM at 2021 Digital Medicine & Medtech Showcase](https://www.sonicincytes.com/sonic-incytes-to-introduce-velacurtm-at-2021-digital-medicine-medtech-showcase/) - Sonic Incytes Medical Corp. is pleased to present its breakthrough liver health assessment solution, VelacurTM, at the Digital Medicine & Medtech Showcase 2021, part of Biotech Showcase™ 2021 and during the 39th Annual JP Morgan Healthcare Conference, taking place the second week of January. Affecting 100 million Americans by 2030, and millions more around the - [Live Webinar: The Role of Next-Gen NITs in NAFLD/NASH](https://www.sonicincytes.com/live-webinar-the-role-of-next-gen-nits-in-nafld-nash/) - Sonic Incytes Medical Corp. is pleased to host a live educational webinar on The Role of Next-Gen Non-Invasive Tests (NITs) in NAFLD/NASH. Join presenter Dr. Robert Gish, a renowned hepatologist and gastroenterologist, to learn about: Non-Invasive Tests (NITs) for Detecting NAFLD/NASH Role of NITs in Staging Fibrosis & Quantifying Steatosis Best Practices for Integrating NITs - [Further Studies Underway to Demonstrate Clinical Value of VelacurTM](https://www.sonicincytes.com/further-studies-underway-to-demonstrate-clinical-value-of-velacurtm/) - Sonic Incytes is proud to expand its collaboration with key centers of clinical excellence in chronic liver disease in North America to continue evaluating its diagnostic solution, VelacurTM. Indiana University (IU) has recently joined Sonic Incytes’ Early Access Program to trial VelacurTM. IU aims to evaluate VelacurTM in comparison to other methods in assessing non-alcoholic - [VelacurTM Results Presented at AASLD’s The Liver Meeting 2020](https://www.sonicincytes.com/velacurtm-results-presented-at-aaslds-the-liver-meeting-2020/) - At the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2020, Sonic Incytes presented the results of its clinical trial using the VelacurTM prototype, a novel medical technology that measures liver elasticity and attenuation. This trial was an initial study to evaluate the ability of the VelacurTM prototype to differentiate between - [Register for Elastography Webinar Series](https://www.sonicincytes.com/register-for-elastography-webinar-series/) - During The Liver Meeting Digital Experience™ 2020, Sonic Incytes Medical Corp. invites you to a professional development webinar series starting November 15: The Latest Advances in Elastography and its Potential in NAFLD and NASH. Join presenters Dr. Rohit Loomba (University of California, San Diego), Dr. Michael Curry (Beth Israel Deaconess Medical Center, Boston) and Moderator - [VelacurTM at AASLD’s The Liver Meeting 2020](https://www.sonicincytes.com/velacurtm-at-aaslds-the-liver-meeting-2020/) - Join Sonic Incytes at AASLD’s The Liver Meeting 2020, November 13-16, to find out more about how we’re creating accessible and affordable diagnostic solutions. - [Sonic Incytes Recognized as a Ready to Rocket Life Science Company](https://www.sonicincytes.com/sonic-incytes-recognized-as-a-ready-to-rocket-life-science-company/) - Poised for success with its breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease, Sonic Incytes Medical Corp. has been named a top technology company in the 18th Annual “Ready to Rocket” list published by Rocket Builders today. - [Visit Us at the Digital International Liver CongressTM](https://www.sonicincytes.com/visit-us-at-the-digital-international-liver-congresstm/) - Sonic Incytes is proudly presenting at the EASL Digital International Liver CongressTM, August 27-29, 2020. - [Sonic Incytes presents at 2020 Canadian Liver Meeting](https://www.sonicincytes.com/sonic-incytes-presents-at-2020-canadian-liver-meeting/) - Sonic Incytes is proudly presenting at the Canadian Liver Meeting, February 28 to March 1, 2020, in Montreal, Canada. - [Sonic Incytes Accepted Into Boston CTA](https://www.sonicincytes.com/sonic-incytes-accepted-into-boston-cta/) - Sonic Incytes Medical Corp. is pleased to announce it has been selected to participate in the Canadian Technology Accelerator (CTA) 2020 program, along with 10 other promising start-ups in tech and life sciences from across Canada. ## Pages - [VELACUR ONE™-home](https://www.sonicincytes.com/) - VELACUR ONE AI-Guided Ultrasound Elastography for Assessments of Chronic Liver Diseases Request a Demo Watch a Video AI-Guided Ultrasound Elastography for Assessments of Chronic Liver Diseases Velacur ONE is a point-of-care device that measures key indicators for MASLD and MASH, comparable to both invasive and non-invasive gold standards*. *(ie. MRE/MRI-PDFF and biopsy) Request a Demo - [About Us](https://www.sonicincytes.com/about-us/) - About Us At Sonic Incytes, we’re transforming how liver health is measured About Us At Sonic Incytes, we’re transforming how liver health is measured Founded in 2017 in Vancouver, British Columbia, Sonic Incytes Medical Corp. set out to make liver assessment faster, simpler, and more accurate. Today, we are a team of clinicians, engineers, and - [Resource Library](https://www.sonicincytes.com/resource-library/) - ResourceLibrary Access a collection of clinical posters, publications, and educational resources that highlight the scientific foundation and clinical validation of Velacur. Our Velacur™ resource library brings together the growing body of evidence that supports the use of Velacur as a non-invasive tool for evaluating liver health. Within this collection you will find peer-reviewed publications, scientific posters, and clinical - [Velacur™](https://www.sonicincytes.com/velacur/) - Assess liver disease at the point of care with VELACUR™ VELACUR is an AI guided 3D S-WAVE ultrasound elastography device that measures the key indicators of fatty liver disease: liver stiffness, attenuation and velacur determined fat fraction (VDFF). Request a Demo Key Resources and Latest News Liver Elastography: CPT Codes, Common Mistakes & Best Practices - [Technology behind Velacur ONE](https://www.sonicincytes.com/technology-behind-velacur-one/) - The Technology Behind VELACUR™ We designed VELACUR as non-invasive test for liver stiffness, attenuation and velacur determined fat fraction (VDFF)that is accurate, affordable and available at the point of care. AI Guidance and S-WAVE technology go further to set VELACUR apart from alternative solutions. Here’s how. Easily integrated at point-of-care AI Guidance VELACUR uses artificial - [Thank you - demo](https://www.sonicincytes.com/thank-you-demo/) - Thank you for booking a demo! We’re looking forward to showing you how VELACUR works. We will be in touch soon to arrange a time. While you’re waiting, here are some documents that might be helpful. Product brochure Reimbursement guide - [Watch Velacur ONE in Action](https://www.sonicincytes.com/watch-velacur-one-in-action/) - [Thank you - demo - Velacur ONE](https://www.sonicincytes.com/thank-you-demo-velacurone/) - Thank you for booking a demo! We’re looking forward to showing you how VELACUR ONE works. We will be in touch soon to arrange a time. While you’re waiting, here are some documents that might be helpful. Product brochure Reimbursement guide - [Team](https://www.sonicincytes.com/team/) - Leadership We are led by an experienced leadership team, as well as directors and advisors with extensive knowledge of medtech entrepreneurship, ultrasound and medical imaging, artificial intelligence, machine learning, liver disease, metabolic health and US healthcare. Barry Allen President & Chief Executive Officer Serial founder and operator of medtech, software and digital companies. Richard Rawnsley - [Sales Demo Request Form](https://www.sonicincytes.com/sales-request-extra-demo-support/) - Submit a request for extra demo support Account Details Enter Account Details Requested by Your email Practice name Current product None Fibroscan Hepatus Other product # of Doctors/Sites # of Operators # of Current scans per week # of Patients per day # of Potential new scanners Timeline for purchase Expectations Set Expectations Set Training - [News](https://www.sonicincytes.com/news/) - News & Insights Categories News Categories Blog Events Investors News Releases FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases Read More » August 12, 2025 Liver Elastography: CPT Codes, Common Mistakes & Best Practices for Billing Read More » February 18, 2025 - [Resources New](https://www.sonicincytes.com/resources-new/) - Resources Keep up to date with us. Webinars Latest News Educational Videos Brand Assets / Media Kit On-Demand Webinars Learn about the latest advances in assessing and managing liver disease, featuring key opinion leaders and subject matter experts. Key Takeaways from AASLD 2024 December 17, 2024, 9AM PT Liver health experts Dr. Naim Alkhouri and - [Clinical Research](https://www.sonicincytes.com/research/) - Clinical Research We’re proud to collaborate with key centers of excellence in chronic liver disease across North America to evaluate our solution through rigorous clinical research. If you’re interested in conducting research with Velacur, please submit an application for clinical research support here. Peer reviewed publications Accuracy of Velacur in Assessing MASLD and MASH Patients - [Providers](https://www.sonicincytes.com/providers/) - VELACUR™ for Providers As rates of fatty liver disease rise and with new treatments for MASLD and MASH becoming available, the need for a high-quality, non-invasive, point of care imaging tool is greater than ever. VELACUR offers superior economics, easy to use pre-installed software and comprehensive training, making implementing our ultrasound elastography device an easy - [Resources for Patients and Providers](https://www.sonicincytes.com/patient-and-provider-resources/) - Velacur Resources for Patients and Providers Welcome! Thank you for choosing Velacur. On this page you’ll find resources with more information about how to prepare for your Velacur exam, how to interpret Velacur results and more.Need support? We’re happy to help, reach out to us via email at support@sonicincytes.com or give us a call at - [Velacur Determined Fat fraction](https://www.sonicincytes.com/velacur/vdff/) - Introducing VDFF Velacur Determined Fat Fraction delivers similar clinical utility to MRI-PDFF at the point of care, transforming the management of hepatic steatosis. VDFF is an innovative measurement tool integrated into the Velacur® software that combines quantitative measures of ultrasound attenuation and backscatter. VDFF has an outstanding accuracy (AUC) of 95% as a classifier of patients - [Contact Us](https://www.sonicincytes.com/contact-us/) - Contact Us Interested in investing, partnering,purchasing or finding out moreabout our product? Let’s connect! Inquiries First Name Last Name Organization Email What are you inquiring about? Select a category General Inquiry Request a Demo / Sales Inquiry Customer Support Partnership Inquiry Investment Inquiry Clinical Trial Participation Media Inquiry How did you hear about us? Select - [Technology behind Velacur](https://www.sonicincytes.com/technology/) - The Technology Behind VELACUR™ We designed VELACUR as non-invasive test for liver stiffness, attenuation and velacur determined fat fraction (VDFF)that is accurate, affordable and available at the point of care. AI Guidance and S-WAVE technology go further to set VELACUR apart from alternative solutions. Here’s how. Full touch screen with pre-installed AI-guided software. Like MRE, - [Security](https://www.sonicincytes.com/security/) - Security Software Bill of Materials The following lists “Off-the-Shelf” software (OTS SW) Components for the Velacur Product Version 2.8.3 with Windows 11 operating system.OTS applications:Microsoft Visual C++ 2017 Redistributable Package (x64)Microsoft Foundation Class Library (MFC)Windows 11 ProBitlockerWindows Defender FirewallMicrosoft AntivirusRemote Desktop utilitiesCUDACULAcuDNNAWS CloudS3 BucketAWS SDKPythonOpenCVTensorflowGTKInkspace7zipLog4cppSparkFunTTPsvgLibpyPDF2MatplotlibduePWMSoftwireDueFlashStorage Vulnerabilities There are no known vulnerabilities at this time. End of Life - [Patients](https://www.sonicincytes.com/patients/) - Information for Patients Fatty liver disease is the fastest-growing segment of chronic liver disease. It is estimated that more than one in three adults suffer from Metabolic Dysfunction-Associated Steatotic Liver Disease aka. MASLD (previously non-alcoholic fatty liver disease, NAFLD)1. With early detection and intervention fatty liver disease can be halted or even reversed. About Fatty - [Clinical Research Support Application](https://www.sonicincytes.com/clinical-research-support-application/) - Clinical Research Support Application Name: Institution: Title of potential project: Summary of project: Budget: Briefly describe your clinic: Do you have a separate clinical research department and clinical research staff in your clinic? What type of clinical research have you done at your clinic? What other types of devices or biomarkers do you currently use - [Watch Velacur in Action](https://www.sonicincytes.com/velacur-video/) - [Velacur Demo](https://www.sonicincytes.com/velacur-demo/) - Request a Demo of Velacur™️ Watch our 3D liver health assessment tool in action. - [Terms of Use](https://www.sonicincytes.com/terms-of-use/) - Terms of Use Welcome to Sonic Incytes Medical Corp. These terms of use contain important information you should have when you visit sonicincytes.com and any of our other websites (collectively “our website”).Please read these terms of use carefully before using our website as they represent a binding agreement (the “Agreement”) between each user of our - [Privacy Policy](https://www.sonicincytes.com/privacy-policy/) - Privacy Policy Thank you for visiting our website. This Privacy Policy tells you how we use personal information collected on this website – www.sonicinyctes.com. By using this website, you are accepting the practices described in this Privacy Policy, therefore please read this page carefully before using the website or submitting any personal information.This Policy may - [Media Kit](https://www.sonicincytes.com/media-kit/) - Media Kit Resources to get youstarted on crafting yourstory about Sonic Incytes. ABOUT US Product Brochure Download S-WAVE White Paper Download Fact Sheet Download VIDEOS Procedure Patient Journey AUDIO Surfing the NASH Tsunami Podcast Dr. Nezam Afdhal of BIDMC discusses the Velacur™ prototype clinical trial. November 14, 2020 Surfing the NASH Tsunami Podcast Dr. Michael - [Webinar Registration](https://www.sonicincytes.com/webinar-registration/) - Webinar Registration Expand your knowledge. No upcoming webinars at this time. Come back again soon! Register to Attend the Webinar First Name Last Name Title Organization Email Phone Referred By How did you hear about this event?* Advertisement Article Conference Email Internet Search (e.g. Google) Phone Call Social Media (e.g. LinkedIn) Word of Mouth Other - [Company](https://www.sonicincytes.com/company/) - Company We deliver health insightsyou can count on. About Us Recognizing the rise of fatty liver disease, we’ve made it our mission to make liver health a new vital sign.Our novel, portable, handheld solution assesses liver attenuation with ultrasound, and liver stiffness with technology similar to that of MRI elastography, the current non-invasive gold standard. - [Thank you for confirming receipt of Velacur](https://www.sonicincytes.com/thank-you-for-confirming-receipt-of-velacur/) ## My Templates - [Bio - Caitlin Schneider](https://www.sonicincytes.com/?elementor_library=bio-caitlin-schneider) - Content area - [Bio - Julio Lobo](https://www.sonicincytes.com/?elementor_library=bio-julio-lobo) - Content area - [Bio - Kevin Murrey](https://www.sonicincytes.com/?elementor_library=bio-kevin-murrey) - Content area - [Bio - Richard Rawnsley](https://www.sonicincytes.com/?elementor_library=bio-richard-rawnsley) - Content area - [Bio - Barry Allen](https://www.sonicincytes.com/?elementor_library=bio-barry-allen) - Content area - [Bio - Kenneth Mortisugu](https://www.sonicincytes.com/?elementor_library=bio-kenneth-mortisugu) - Content area - [Bio - Natalie Dakers](https://www.sonicincytes.com/?elementor_library=bio-natalie-dakers) - Content area - [Bio - Paul Geyer](https://www.sonicincytes.com/?elementor_library=bio-paul-geyer) - Content area - [Bio - Naim Alkhouri](https://www.sonicincytes.com/?elementor_library=bio-naim-alkhouri) - Content area - [Bio - Nezdam Afdahl](https://www.sonicincytes.com/?elementor_library=bio-nezdam-afdahl) - Content area - [Bio Popup Template](https://www.sonicincytes.com/?elementor_library=bio-popup-template) - Content area - [Site Footer](https://www.sonicincytes.com/?elementor_library=site-footer) - Content area - [Resources - Product Brochures](https://www.sonicincytes.com/?elementor_library=resources-product-brochures) - Download All Velacur Reimbursement Guide Download Velacur ONE Interpretation Guide Download Velacur ONE Product Brochure Download Velacur Determined Fat Fraction Download Velacur vs Transient Elastography Download CDC Case Study Download White Paper - Velacur Shear Wave Absolute Vibro-Elastography Download Velacur Patient Brochure Download Velacur For MASH Treatment Eligibility Download Download All - [Resources - Posters](https://www.sonicincytes.com/?elementor_library=resources-posters) - For Investigational Use Only Download All Validation of Velacur Elasticity (S-WAVE) and Attenuation (ACE) Against MRE and MRI-PDFF in Patients with Clinically Diagnosed MASLD or MASH ACG 2025 Download Velacur VDFF Outperforms FibroScan CAP in Assessment of Liver Steatosis in a Large Cohort of Patients with MASLD and MASH DDW 2025 Download The Performance of - [Resources - User Guides](https://www.sonicincytes.com/?elementor_library=resources-user-guides) - Download All Velacur ONE Instructions for Use Download Velacur ONE Troubleshooting Guide Download Velacur ONE Set Up Guide Download Velacur ONE Component Guide Download Velacur ONE Troubleshooting Ultrasound Images Download Velacur ONE Procedure Guide Download Velacur ONE Organ Guide Settings Download Wave Quality Guide Download Download All - [Resources - Publications 3](https://www.sonicincytes.com/?elementor_library=resources-publications-3) - Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard Diagnostics 2025 Read Now Deep Learning Based Shear Wave Detection and Segmentation Tool for Use in Point-of-Care for Chronic Liver Disease Assessments Ultrasound in Medicine & Biology 2024 Read Now Methods and Validation of Velacur Determined Fat Fraction in Patients - [Site Header](https://www.sonicincytes.com/?elementor_library=site-header) - Content area - [Default Kit](https://www.sonicincytes.com/?elementor_library=default-kit-2) - [Resources - Publications 2](https://www.sonicincytes.com/?elementor_library=resources-publications-2-2) - Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard Diagnostics 2025 Read Now Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard Diagnostics 2025 Read Now Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard Diagnostics 2025 - [Resources - Publications](https://www.sonicincytes.com/?elementor_library=resources-publications) - Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard Diagnostics 2025 Read Now - [Single News Template](https://www.sonicincytes.com/?elementor_library=single-news-template) - News Single News Template October 5, 2023 News Single News Template October 5, 2023 Sync up with Sonic Be in-the-know on all our latest news!Subscribe to our e-newsletter. First Name Last Name Organization Email Subscribe Sync up with Sonic Be in-the-know on all our latest news!Subscribe to our e-newsletter. First Name Last Name Organization Email - [Webinar Archive (Default)](https://www.sonicincytes.com/?elementor_library=test) - Webinars Expand your knowledge. Subscribe to our mailing list to be notified about upcoming webinars or scroll down to view previous webinars on-demand On-Demand Webinars Learn about the latest advances in assessing and managing liver disease, featuring key opinion leaders and subject matter experts. December 17, 2024, 9AM PT Liver health experts Dr. Naim Alkhouri - [Investigational Research Access](https://www.sonicincytes.com/?elementor_library=investigational-research-access) - Content area - [Book a demo](https://www.sonicincytes.com/?elementor_library=book-a-demo) - Content area - [Elementor Loop Item #4252](https://www.sonicincytes.com/?elementor_library=elementor-loop-item-2) - [Newsletter Signup Widget](https://www.sonicincytes.com/?elementor_library=newsletter-signup-widget) - First Name Last Name Organization Email Subscribe - [EASL 2023](https://www.sonicincytes.com/?elementor_library=easl-2023-popup) - Content area - [AASLD 2022](https://www.sonicincytes.com/?elementor_library=aasld-2022-popup) - Content area - [DDW 2022](https://www.sonicincytes.com/?elementor_library=ddw-2022-popup) - Content area - [NASH-TAG 2022](https://www.sonicincytes.com/?elementor_library=nash-tag-2022-popup) - Content area - [AASLD 2021](https://www.sonicincytes.com/?elementor_library=aasld-2021-popup) - Content area - [On-Demand Webinar Registration Form](https://www.sonicincytes.com/?elementor_library=on-demand-webinar-form) - Register to View the Webinar First Name Last Name Title Organization Email Phone Referred By How did you hear about this event?* Advertisement Article Conference Email Internet Search (e.g. Google) Phone Call Social Media (e.g. LinkedIn) Word of Mouth Other View Now - [Future Webinar Registration Form](https://www.sonicincytes.com/?elementor_library=future-webinar-registration-form) - Register to Attend the Webinar First Name Last Name Title Organization Email Phone Referred By How did you hear about this event?* Advertisement Article Conference Email Internet Search (e.g. Google) Phone Call Social Media (e.g. LinkedIn) Word of Mouth Other Register Now - [Elementor Loop Item #2647](https://www.sonicincytes.com/?elementor_library=elementor-loop-item) - LATEST NEWS Elementor Loop Item #2647 LATEST NEWS Read More Read More - [Webinar Single (Default)](https://www.sonicincytes.com/?elementor_library=webinar-single-default) - Webinars Expand your knowledge. Back to Webinars Webinar Single (Default) Featured Speaker(s): PrevPreviousWebinar Archive (Default) NextOn-Demand Webinar Registration FormNext Share With Your Network Facebook Twitter LinkedIn Email - [Webinar Registration Section](https://www.sonicincytes.com/?elementor_library=webinar-registration-section) - Register to Attend the Webinar First Name Last Name Title Organization Email Phone Referred By How did you hear about this event?* Advertisement Article Conference Email Internet Search (e.g. Google) Phone Call Social Media (e.g. LinkedIn) Word of Mouth Other Register Now - [Maintenace](https://www.sonicincytes.com/?elementor_library=maintenace) - Thanks for visiting us. Our site is currently down for maintenance. Check back again soon. - [Webinar Video](https://www.sonicincytes.com/?elementor_library=webinar-video) - Content area - [Default Kit](https://www.sonicincytes.com/?elementor_library=default-kit) - [Default Kit](https://www.sonicincytes.com/?elementor_library=default-kit) ## Leaders - [Richard Rawnsley, CPA, CA](https://www.sonicincytes.com/leader/neville-israel/) - Former Finance and Operations Executive at Alpha Foods, Hootsuite and Ernst & Young - [Dr. Naim Alkhouri](https://www.sonicincytes.com/leader/dr-naim-alkhouri/) - Chief Medical Officer and Director of the Fatty Liver Program, Arizona Liver Health - [Dr. Stephen Harrison](https://www.sonicincytes.com/leader/dr-stephen-harrison/) - Medical Director, Pinnacle Clinical Research and President, Summit Clinical Research - [Dr. Nezam Afdhal](https://www.sonicincytes.com/leader/dr-nezam-afdhal/) - Head of Gastroenterology, Beth Israel Deaconess Medical Center - [Natalie Dakers (Board Chair)](https://www.sonicincytes.com/leader/natalie-dakers/) - Health Sciences Entrepreneur & Investor Former Founding President & CEO of Accel-Rx Health Sciences Accelerator, CDRD Ventures - [Barry Allen](https://www.sonicincytes.com/leader/barry-allen-2-2/) - Serial founder and operator of medtech, software and digital companies - [Paul Geyer](https://www.sonicincytes.com/leader/paul-geyer/) - CEO, Discovery Parks and Nimbus Synergies - [Dr. Kenneth Moritsugu](https://www.sonicincytes.com/leader/dr-kenneth-moritsugu/) - Former US Deputy Surgeon General, Rear Admiral US PHS - [Julio Lobo](https://www.sonicincytes.com/leader/julio-lobo/) - Formerly with BC Cancer Agency - [Dr. Robert Rohling](https://www.sonicincytes.com/leader/dr-robert-rohling/) - UBC ECE Professor, ICICS Director with expertise in Ultrasound, AI, Machine Learning - [Dr. Tim Salcudean](https://www.sonicincytes.com/leader/dr-tim-salcudean/) - UBC ECE Professor, Laszlo Chair with expertise in Ultrasound, Robotics - [Barry Allen](https://www.sonicincytes.com/leader/barry-allen/) - Serial founder and operator of medtech, software and digital companies ## Webinars - [Key Takeaways from AASLD 2024](https://www.sonicincytes.com/webinars/key-takeaways-from-aasld-2024/) - December 17, 2024, 9AM PT Liver health experts Dr. Naim Alkhouri and patient advocate Michael Betel share highlights and key insights from the world’s leading forum on liver disease! - [Diabetes & Fatty Liver Disease: What Every Liver Specialist Should Know](https://www.sonicincytes.com/webinars/diabetes-fatty-liver-disease/) - August 22, 2023, 2PM PT Join Key Opinion Leader and renowned endocrinologist Dr. Kenneth Cusi for an informative webinar that will unpack the relationship between diabetes and fatty liver disease. - [Becoming Practice-Ready for Imminent NASH Drug Approvals](https://www.sonicincytes.com/webinars/becoming-practice-ready-for-nash-drug-approvals/) - March 29, 2023, 9AM PT Listen to expert panel Dr. Stephen Harrison, Dr. Maru/Mary Rinella, and Dr. Mazen Noureddin as they discuss the practical implications of a NASH drug approval. - [A New Era of NASH Management](https://www.sonicincytes.com/webinars/a-new-era-of-nash-management-webinar/) - December 13, 2022, 9AM PT Discover how recent advancements in NITs and NASH therapeutics could change the landscape of the disease. - [The Multidisciplinary Approach: An Optimal Model of Care for NASH](https://www.sonicincytes.com/webinars/an-optimal-model-of-care-for-nash/) - September 22, 2021, 9AM PT Learn how a multidisciplinary approach will provide an optimal model of care for fatty liver disease patients. - [Owning NAFLD Via Reimbursement Optimization](https://www.sonicincytes.com/webinars/owning-nafld-via-reimbursement-optimization/) - December 8, 2021, 9AM PT Discover how providers and payers can work together to address the emerging fatty liver disease epidemic, resulting in better patient outcomes with improved reimbursement. - [Alternative Therapies for NASH](https://www.sonicincytes.com/webinars/alternative-therapies-for-nash/) - September 28, 2022, 10AM PT/1PM EST Listen to Key Opinion Leader Dr. Naim Alkhouri to learn about alternative therapies that can help your NASH patients with metabolic disorders. - [Novel Tools for Managing Metabolic Syndrome](https://www.sonicincytes.com/webinars/novel-tools-for-managing-metabolic-syndrome/) - March 24, 2022, 9AM PT Learn about novel tools for assessing and managing patients with metabolic syndrome in your practice. - [Advances in NASH Drugs & The Role of NITs](https://www.sonicincytes.com/webinars/advances-in-nash-drugs-the-role-of-nits/) - June 10, 2021, 8:30AM PT Learn about promising therapies on the horizon to manage and treat NASH and the role of non-invasive tests. - [Scope Forward: The Future of GI is Now in Your Hands](https://www.sonicincytes.com/webinars/the-future-of-gi/) - July 21, 2021, 9AM PT Learn about the trends shaping the future of GI, and how you can leverage these trends to grow your GI practice. ## Listing Items/Components - [News Listings](https://www.sonicincytes.com/?jet-engine=news-listings) - News Listings Read More Read More - [Directors and Advisors Listings](https://www.sonicincytes.com/?jet-engine=directors-and-advisors-listings) - FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases - [Leadership Listing](https://www.sonicincytes.com/?jet-engine=leadership-listing) - FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases Linkedin-in ## Categories - [News Releases](https://www.sonicincytes.com/category/news-releases/) - We deliver news you can use. - [Events](https://www.sonicincytes.com/category/events/) - [Investors](https://www.sonicincytes.com/category/investors/) - [Blog](https://www.sonicincytes.com/category/blog/) ## Tags - [reimbursement](https://www.sonicincytes.com/tag/reimbursement/) ## Leader Categories - [Leadership](https://www.sonicincytes.com/leaders-categories/leadership/) - [Directors](https://www.sonicincytes.com/leaders-categories/directors/) - [Clinical Advisors](https://www.sonicincytes.com/leaders-categories/clinical-advisors/)